Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

NCT02194348 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the present study was to obtain information about safety, tolerability and pharmacokinetics of BIBN 4096 BS after single subcutaneous administration of increasing doses in healthy male and female volunteers

Timeline

Start: 2000-02
Primary completion: 2000-03
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIBN 4096	Unknown	—	Subcutaneous

Indications

No indication recorded.